CAR-NK cell therapy for glioblastoma: what to do next?

Frontiers in Oncology

Oncology

Jiao Zhu¹  Yong Zhang¹  Hongxin Deng¹  Qi Xiong¹ 

[1] Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China;

关键词: CAR-NK cells;    glioblastoma;    natural killer cells;    immunotherapy;    cell therapy;   

DOI  :  10.3389/fonc.2023.1192128

 received in 2023-03-23, accepted in 2023-05-29,  发布年份 2023

来源: Frontiers

【 摘 要 】

Glioblastoma is a malignant tumor with the highest morbidity and mortality in the central nervous system. Conventional surgical resection combined with radiotherapy or chemotherapy has a high recurrence rate and poor prognosis. The 5-year survival rate of patients is less than 10%. In tumor immunotherapy, CAR-T cell therapy represented by chimeric antigen receptor-modified T cells has achieved great success in hematological tumors. However, the application of CAR-T cells in solid tumors such as glioblastoma still faces many challenges. CAR-NK cells are another potential adoptive cell therapy strategy after CAR-T cells. Compared with CAR-T cell therapy, CAR-NK cells have similar anti-tumor effects. CAR-NK cells can also avoid some deficiencies in CAR-T cell therapy, a research hotspot in tumor immunity. This article summarizes the preclinical research status of CAR-NK cells in glioblastoma and the problems and challenges faced by CAR-NK in glioblastoma.

【 授权许可】

Unknown   
Copyright © 2023 Xiong, Zhu, Zhang and Deng